Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Pancreatic Neoplasms 679Carcinoma, Non-Small-Cell Lung 324Neoplasms 168Breast Neoplasms 163Urinary Bladder Neoplasms 157Lung Neoplasms 157Neoplasm Metastasis 139Cholangiocarcinoma 112Ovarian Neoplasms 106Biliary Tract Neoplasms 92Lymphoma, Large B-Cell, Diffuse 73Nasopharyngeal Carcinoma 70Lymphoma 66Sarcoma 63Recurrence 62Gallbladder Neoplasms 60Carcinoma, Transitional Cell 55Triple Negative Breast Neoplasms 54Hodgkin Disease 52Colorectal Neoplasms 49Fallopian Tube Neoplasms 48Lymphoma, Non-Hodgkin 47Adenocarcinoma 45Bile Duct Neoplasms 40Carcinoma, Ovarian Epithelial 31Non-Muscle Invasive Bladder Neoplasms 30Uterine Cervical Neoplasms 28Carcinoma 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma of Lung 27

Interventions

Gemcitabine 5130-nm albumin-bound paclitaxel 3nimotuzumab 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Albumin-Bound Paclitaxel 2surufatinib 1napabucasin 1irinotecan sucrosofate 1ensituximab 1Taxes 1S 1 (combination) 1Radiofrequency Ablation 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Pancreatic cancer, adult × Gemcitabine × Clear all
NCT07436741 2026-02-27

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Not yet recruiting
106 enrolled
Gastrointestinal

Pancreatic cancer, adult

NCT06584227 2025-12-08

ACPC

Jinling Hospital, China

Phase 2 Recruiting
45 enrolled
Gastrointestinal

Pancreatic cancer, adult, Pancreatic Neoplasms

NCT03854110 2025-09-11

Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

Geistlich Pharma AG

Phase 1 Active not recruiting
64 enrolled
Gastrointestinal

Pancreatic cancer, adult

NCT01834235 2025-05-07

QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer

Precision Biologics, Inc

Phase 1/2 Terminated
81 enrolled 13 charts
Gastrointestinal

Pancreatic cancer, adult, Pancreatic Neoplasms

NCT02231723 2023-11-18

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
139 enrolled
Gastrointestinal

Pancreatic cancer, adult, Digestive System Neoplasms, Endocrine Gland Neoplasms, Adenoma, Islet Cell, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Islet Cell, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡